R&D / R&D 파이프라인

 

 

 

 

 

 

 

On

 

 

Infectious Disease

J2H-1801

J2H-1701

J2H-1901

J2H-1702

J2H-1705

J2H-1704

*Rare Disease

Oncology

**Incrementally Modified Drug(IMD)

Hit-to-Lead

Multiple Sclerosis

Immunotherapy

OAB

HCV

NASH / NAFLD

ALS

Lead Optimization

Non-Clinical

Clinical

* In this context Rare disease does not only refer to the orphan disease, but also includes indication which applies to Fast Track, Breakthrough Therapy, Accelerated Approval, Priority Review

** IMD refers to which could be developed through 505(b)(2) Pathway (Prodrug, Single Enantiomer...)

Copyright © 2014-2018 J2H Biotech Company All rights reserved.

우리의 미션은 "더 나은 의약품을 개발하여 인류의 건강 증진에 기여하는 것이다."

우리의 비젼은 "희귀병과 난치병의 미충족 수요(Unmet Needs)의 해결책(Solution)을 제시하는 것이다."

 

경기도 수원시 권선구 산업로 156번길 142-10 (고색동631) 수원벤처벨리 II B동 210(본사) 210-212(연구소)

TEL)031-5182-8070,8071  FAX)031-5182-8080